Table 3 Comparison of women (n = 78) and men (n = 90) on discontinuations of antiretrovirals due to side effects over the past 6 months
| Â | Women(%) | Men(%) | Â |
|---|---|---|---|
Discontinuations | 19 | 18 | Â |
Switch | 10 | 9 | Â |
Pause | 9 | 9 | Â |
Antiretovirals | Â | Â | Â |
Lamivudine | 12* | 2* | Â |
Stavudine | 6 | 3 | Â |
Lopinavir + Ritonavir boost | 5* | 0* | Â |
Zidovudine | 4 | 2 | Â |
Tenofovir | 4 | 1 | †Other antiretrovirals included single cases of Nevirapine and Emtricitabine in women and men, and Didanosine, Tripanavir + Ritonavir boost, and Fuzeon in men. |
Abacavir | 4 | 1 | Â |
Atazanavir + Ritonavir boost | 3 | 0 | Â |
Other antiretrovirals †| 3 | 6 | ††Other side effects included single cases of amenorrhea, teratotoxic potential, adherence barrier during vacation, changes in taste, and resistance mutations in women, and kidney stones, pain at injection site, nightmares, and depression in men. |
Side effects | Â | Â | Â |
Lipodystrophy | 8 | 2 | Â |
Metabolic changes | 4 | 3 | Â |
Polyneuropathy | 1 | 3 | Â |
Gastointestinal problems | 4 | 7 | Chi square test indicates significant difference between men and women at: |
Skin problems | 3 | 1 | Â |
Other side effects ††| 6 | 4 | *p < .05 |